Not really, holders had a fit when DCB/JC told us that there wouldn't be any POC CPACS data until 2026, and that it was going to be produced from a trial we didn't have the money to fund... they were sending shareholders off for slaughter (see any one of Paul Hopper's companies).
There's a reason AML isn't scheduled to start until after RC220 has been clinically validated as safe. AML is the lowest risk, lowest return pathway with a limited patient pool. What difference does it make as to who the lead investigator is if the trial is going to commence post CPACS validation?
It boggles my mind that people can't seem to digest the upside opportunity of CPACS vs Zan + Decitabine. The AML opportunity is immaterial to the commercial upside of CPACS.
RAC Price at posting:
$1.66 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)